Safety and Efficacy of AR1005 in Patients with Lewy Body Disease

Launched by YONSEI UNIVERSITY · Jul 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AR1005 for patients with Lewy Body Dementia, a condition that affects thinking and movement. The trial aims to find out if AR1005 can help improve memory, behavior, and overall brain function in patients who have cognitive impairment due to this disease. Researchers are looking for 60 volunteers aged 60 and over who can communicate in Korean and have been diagnosed with Lewy Body Dementia or mild cognitive impairment related to it. To participate, volunteers must also have certain levels of cognitive decline, as measured by a simple mental health test.

Participants in the trial will receive either the treatment or a placebo (a non-active version) without knowing which one they got, in a process called "double-blind." They will be monitored closely to see how the treatment affects their thinking and behavior, as well as their movement and brain activity. It’s important for participants to have a caregiver who can help support them throughout the study. As always, potential participants should consult with their doctor to ensure they meet the eligibility criteria and understand what their involvement in this study entails.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • men and women over the age of 60
• • Communication in Korean is possible and the purpose and process of the study are fully understood and agreed
• • Total score of 26 points or less in the simplified mental health assessment (K-MMSE)
• • Dementia Clinical Evaluation Scale (CDR) Total score of 0.5 or higher
• • Medical history, neurological examination, hematologic examination, Seoul neuropsychological examination 2nd edition, brain magnetic resonance imaging suspected of cognitive impairment due to dementia with Lewy bodies as the cause of cognitive decline
• • i. Lewy body dementia
• • 1. In accordance with the guidelines for the 4th report of the Dementia with Lewy Bodies Consortium (DLBC) published in 2017, if it falls under Probable Dementia with Lewy Bodies
• • 2. Required Requirements
• • 1. Dementia, defined as cognitive decline that progresses sufficiently to impair normal social and professional functions or daily life
• • 2. Defects in attention, enforcement, and space-time capabilities are noticeable in the inspection
• • 3. Core clinical features
• • 1. variation in cognitive function
• • 2. vision
• • 3. Parkinson's syndrome: One or more manifestations of sinusitis, stable progress, or stiffness
• • 4. REM sleep behavior disorder
• • 4. Indicative biomarker
• • 1. Decreased intake of dopamine carrier PET-phase nuclear
• • 2. \[I-123\]-MIBG myocardial scintigraphy intake decreased
• • 3. REM sleep behavior disorder according to polymorphic test
• • 5. In the case of two or more key aspects, or one or more key clinical features and one or more indicative biomarkers are satisfied
• • ii. Bulb Lewy body dementia (Prodromal DLB)
• • <!-- -->
• • 1. If it falls under the Probable MCI-LB with a mild cognitive impairment according to the criteria for diagnosing precursor Lewy body dementia announced in 2020
• • 2. Required Requirements
• • a. cognitive decline observed when judged by the patient, guardian, or clinician b. Objective cognitive decline (although it is not related to any cognitive domain, it should be mainly related to the deterioration of execution function and space-time ability)
• • 3. Core clinical features
• • 1. variation in cognitive function
• • 2. vision (nap, dazed, same document, angry)
• • 3. Parkinson's syndrome: One or more manifestations of sinusitis, stable progress, or stiffness
• • 4. REM sleep behavior disorder
• • 4. Indicative biomarker
• • a. Decreased intake of dopamine carrier PET-phase nuclear b. \[I-123\]-MIBG myocardial scintigraphy intake decreased c. REM sleep behavior disorder according to polymorphic test
• • 5. The leading mild cognitive impairment due to dementia with Lewy bodies has two or more key features or satisfies one or more key clinical features and one or more indicative biomarkers
• • ⑥ Patients with caregivers who are in regular contact with the subject (Note: caregivers may support the subject during the clinical trial \[compliance supervision and reporting of the subject's status\], defined as those who spend at least 8 hours per week with the subject)
• • ⑦ Patients who can walk or move with walking aids (i.e., walkers, canes, or wheelchairs)
• • ⑧ Patients with sufficient vision, hearing, language skills, motor skills, and comprehension to follow the examination procedure as judged by the tester (Aids such as glasses and hearing aids are allowed)
• • ⑨ an examination Patients who have voluntarily decided to participate in this clinical trial and obtained the consent of the subject in writing from both the subject and the subject's legal representative (where written consent is not available, the tester shall keep a record of the matters that the subject has verbally agreed to participate in the trial)
• Exclusion Criteria:
• • In hematologic and brain magnetic resonance imaging tests conducted within 6 months, other causes of cognitive decline such as neurosyphilis, hypo/hyper-throidism, metabolic encephalopathy, brain tumor, acute cerebral hemorrhage, acute cerebral infraction, and Wernicke's encephalopathy are suspected
• • Subjects who are or are suspected of having an irritable allergy to AR1005-KRP2-01
• • If you are already on antistatic medication
• • A person who cannot perform a brain magnetic resonance image (but if there is a brain magnetic resonance image taken within one year, the brain magnetic resonance image can be omitted)
• • voluntary Employees directly involved in this clinical study or their immediate family members who find it difficult to participate
• • If there is a history of psychiatric disorders: major effective disorder, schizophrenia, schizo-effective disorder
• • ⑦ If an electroencephalogram cannot be performed
• • ⑧ Patients who are already taking acetylcholinesterase inhibitor (donepezil and rivastigmine) or taking it in patch form (but can change to rivastigmine PO to participate in the study)
• • ⑨ Patients with moderate to severe liver disorder (Child-Pugh grade B) and dialysis due to decreased renal functiona patient with end-stage renal impairment receiving
• • ⑩ Patients discontinued administration due to aseptic meningitis associated with AR1005-KRP2-01
• • ⑪ Patients with genetic problems such as galactose intolerance, lactose-degrading enzyme deficiency, or glucose-galactose absorption disorders